Appointment of new Group auditors

RNS Number : 6618V

Allergy Therapeutics PLC

16 April 2021

 

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")

Appointment of new Group auditors

16 April 2021 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapy, today announces, that following a competitive tender process,  BDO LLP ("BDO") has been appointed as its external auditor for the year ended 30 June 2021. The appointment of BDO as auditor for the following financial year will be subject to approval by shareholders at the next Annual General Meeting of the Company.

Grant Thornton UK LLP ("Grant Thornton") has now resigned and has confirmed to the Company that there are no matters which should be brought to the attention of the creditors or shareholders of the Group.   

The Company would like to thank Grant Thornton for its service over the past 13 years.

- ENDS -

For further information, please contact:

Allergy Therapeutics

[phone]

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

Panmure Gordon

[phone]

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

Consilium Strategic Communications

[phone]

Mary-Jane Elliott / David Daley / Ashley Tapp / Olivia Manser

[e-mail]

Stern Investor Relations, Inc.

[phone]

Christina Tartaglia

[e-mail]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m² of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved over 9% compound annual growth since formation, employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com .

 

END

 

 

APPSFUFUIEFSEIL